Inhaler Trainer Efficacy Study

Launched by KORONIS BIOMEDICAL TECHNOLOGIES · Jun 13, 2024

Keywords

ClinConnect Summary

The Inhaler Trainer Efficacy Study is a clinical trial designed to see how well a new device, called the Inhaler Trainer, helps patients learn to use their inhalers properly. This study will involve 140 patients with asthma or chronic obstructive pulmonary disease (COPD) who are being treated at the University of Chicago Medicine. To participate, individuals must be between 18 and 85 years old, have a doctor’s diagnosis of asthma or COPD, and have been prescribed certain inhalers. Importantly, they should not have had any previous training with an inhaler training device.

Participants will receive inhaler education using either the Inhaler Trainer or a brief intervention and will be monitored for their inhaler skills and lung function after six weeks. They will also share their experiences with the device in an interview after this period. This study is not yet recruiting participants, but it aims to find out how effective this new training tool is in helping people manage their respiratory conditions better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-85
• • Physician diagnosis of COPD or asthma
• * Has been prescribed or is being prescribed one of the inhalers listed below (DPI inhaler product, Active pharmaceutical ingredient):
• • 1. Serevent®Diskus®(GSK), Salmeterol
• • 2. Incruse Ellipta (GSK), Umeclidinium
• • 3. Spiriva Handihaler (BIP),Tiotropium
• • 4. Tudorza Pressair (AstraZeneca), Aclidinium
• • Inexperienced with inhaler trainer device (defined by never having had inhaler training using an auxiliary tool besides an actual inhaler and spacer)
• Exclusion Criteria:
• • Physician declines to provide assent
• • Patient unable to provide consent (e.g., history of cognitive impairment, unable to understand English) or declines to provide consent
• • Does not meet inclusion criteria